Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2 Randomized Trial of a Moxifloxacin-Containing Regimen For Treatment of Smear-Positive Pulmonary Tuberculosis in Adults With and Without HIV Infection
Brief Summary: Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and then two drugs for 4 months. New drug regimens that are shorter and effective against drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin (MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively treat TB.


Options:
A: Arm Label: TMC207 Stage 1; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: TMC207 Stage 2; Type: EXPERIMENTAL; Interventions: Drug: TMC207, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Arm Label: Placebo Stage 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis) | Intervention Type: DRUG; Name: TMC207; Assigned to Arm(s): TMC207 Stage 1, TMC207 Stage 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2 | Intervention Type: DRUG; Name: Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis); Assigned to Arm(s): Placebo Stage 1, Placebo Stage 2, TMC207 Stage 1, TMC207 Stage 2
B: Arm Label: experimental group1; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol, Drug: Levofloxacin | Arm Label: experimental group2; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol | Arm Label: Control regimen group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Rifampicin; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Ethambutol; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): experimental group1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Moxifloxacin | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol | Intervention Type: DRUG; Name: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Isoniazid, Rifampin, Pyrazinamide, Ethambutol; Assigned to Arm(s): 2

Answer: C